Last Updated on October 9, 2024 by The Health Master
USFDA Inspection
Zydus Lifesciences, a leading Indian pharmaceutical company known for its cancer therapies, recently announced the conclusion of a USFDA inspection at their injectable manufacturing facility in Jarod, Gujarat.
USFDA Inspection Details
USFDA inspection was conducted from April 15th to April 23rd, 2024.
While the specific details of the 10 observations remain undisclosed, Zydus Lifesciences assured investors in a BSE filing that they will “closely work with the USFDA to address and respond to the observations in an expeditious manner.”
About Zydus Lifesciences
Headquartered in Ahmedabad, India, Zydus Lifesciences Limited is a prominent player in the global pharmaceutical industry.
They specialize in discovering, developing, manufacturing, and marketing a wide range of healthcare therapies, with a strong focus on cancer-related treatments.
Their product portfolio includes cytotoxic drugs, supportive medications, and targeted therapies used to combat various forms of cancer.
Zydus Lifesciences boasts a global workforce exceeding 26,000 employees, with over 1,400 dedicated scientists actively engaged in research and development (R&D).
This significant investment in R&D fuels their innovative approach to healthcare solutions.
Impact and Future Developments
The nature of the observations during USFDA inspection and their potential impact on Zydus Lifesciences’ operations remain to be seen.
The company’s prompt response indicates a commitment to resolving the issues efficiently and maintaining compliance with US regulatory standards.
Investors are advised to monitor the situation for further updates as Zydus Lifesciences addresses the observations pointed out during USFDA inspection.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Lupin Receives EIR from USFDA for its Aurangabad Facility
USFDA Inspection: At Marksans with 5 inspectional observations
USFDA Inspection: Successfully Concluded at Piramal Pharma
USFDA Inspection: At Granules India with Zero observations
Pharma Industry to Achieve Global Standards with Schedule M Compliance
Isopropyl Alcohol Imports Get a Boost: Safeguard Measures Lifted in India
Lupin Receives EIR from USFDA for its Aurangabad Facility
Drug recall: Sapropterin Dihydrochloride recalled over potency concerns
Govt includes more Special Invitees into Committee for Pricing framework
USFDA Strengthens Collaboration with CDSCO
USFDA approval granted for this Eye Infection treatment
India to finalise List of OTC Drugs
DCC: Take action to Curb Antimicrobial Resistance (AMR) in India
Govt Job: For Pharma Graduates as Junior Analyst (361) posts
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
